The Use of Progestogen in the Treatment of Metastatic Carcinoma of the Kidney and Uterine Body

The effect of the progestogen medroxyprogesterone acetate on metastases from renal, endometrial and other tumours has been studied in 25 patients. Seven patients with renal and endometrial tumours had a useful response, pulmonary metastases and a large primary renal tumour showing the greatest effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Paine, C. H., Wright, F. W., Ellis, F.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1970
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2008579/
https://www.ncbi.nlm.nih.gov/pubmed/5451569
_version_ 1782135944999075840
author Paine, C. H.
Wright, F. W.
Ellis, F.
author_facet Paine, C. H.
Wright, F. W.
Ellis, F.
author_sort Paine, C. H.
collection PubMed
description The effect of the progestogen medroxyprogesterone acetate on metastases from renal, endometrial and other tumours has been studied in 25 patients. Seven patients with renal and endometrial tumours had a useful response, pulmonary metastases and a large primary renal tumour showing the greatest effect. Bony metastases were unaffected by the drug and were treated by local radiotherapy. If a response occurred, it did so within 3 months. IMAGES:
format Text
id pubmed-2008579
institution National Center for Biotechnology Information
language English
publishDate 1970
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20085792009-09-10 The Use of Progestogen in the Treatment of Metastatic Carcinoma of the Kidney and Uterine Body Paine, C. H. Wright, F. W. Ellis, F. Br J Cancer Articles The effect of the progestogen medroxyprogesterone acetate on metastases from renal, endometrial and other tumours has been studied in 25 patients. Seven patients with renal and endometrial tumours had a useful response, pulmonary metastases and a large primary renal tumour showing the greatest effect. Bony metastases were unaffected by the drug and were treated by local radiotherapy. If a response occurred, it did so within 3 months. IMAGES: Nature Publishing Group 1970-06 /pmc/articles/PMC2008579/ /pubmed/5451569 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Articles
Paine, C. H.
Wright, F. W.
Ellis, F.
The Use of Progestogen in the Treatment of Metastatic Carcinoma of the Kidney and Uterine Body
title The Use of Progestogen in the Treatment of Metastatic Carcinoma of the Kidney and Uterine Body
title_full The Use of Progestogen in the Treatment of Metastatic Carcinoma of the Kidney and Uterine Body
title_fullStr The Use of Progestogen in the Treatment of Metastatic Carcinoma of the Kidney and Uterine Body
title_full_unstemmed The Use of Progestogen in the Treatment of Metastatic Carcinoma of the Kidney and Uterine Body
title_short The Use of Progestogen in the Treatment of Metastatic Carcinoma of the Kidney and Uterine Body
title_sort use of progestogen in the treatment of metastatic carcinoma of the kidney and uterine body
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2008579/
https://www.ncbi.nlm.nih.gov/pubmed/5451569
work_keys_str_mv AT painech theuseofprogestogeninthetreatmentofmetastaticcarcinomaofthekidneyanduterinebody
AT wrightfw theuseofprogestogeninthetreatmentofmetastaticcarcinomaofthekidneyanduterinebody
AT ellisf theuseofprogestogeninthetreatmentofmetastaticcarcinomaofthekidneyanduterinebody
AT painech useofprogestogeninthetreatmentofmetastaticcarcinomaofthekidneyanduterinebody
AT wrightfw useofprogestogeninthetreatmentofmetastaticcarcinomaofthekidneyanduterinebody
AT ellisf useofprogestogeninthetreatmentofmetastaticcarcinomaofthekidneyanduterinebody

Ejemplares similares